JACC This Week

This week's edition of JACC This Week brings Dr. Carolyn Lam and Dr. Harlan Krumholz into a deep exploration of a special issue devoted to innovative cardiovascular research emerging from China. As they highlight newly published studies and their global significance, they reflect on how scientific progress accelerates when discoveries are shared across regions and cultures. Their conversation reinforces a central message: advancing cardiovascular health requires collective effort, open exchange, and a commitment to evaluating science based on quality—not geography.

Drs. Carolyn Lam and Harlan Krumholz unpack new JACC research on cardiometabolic health, highlighting how COVID‑19 shaped cardiovascular care, mortality patterns, and disparities. They also break down updated evidence on PREVENT risk equations in young adults, gaps in lipid testing and statin use, and what these findings mean for modern cardiovascular prevention and population health. JACC This Week — impactful science with global insights.

In this episode, Dr. Carolyn Lam and Dr. Harlan Krumholz break down key studies from this week's JACC issue, including new evidence on Chagas‑related heart failure, updated diastolic function guidelines, and the connection between cardiomyopathy gene variants and atrial fibrillation. They also discuss findings on racial and ethnic disparities in England's universal health system and reflect on how emerging AI tools could transform cardiovascular care. A concise, insightful look at major advances shaping modern cardiology and global heart‑health practice.

Dr. Carolyn Lam and Dr. Harlan Krumholz sit down with Dr. Rishi Wadhera to unpack the first-ever JACC Cardiovascular Statistics issue. They explore why this annual report matters, the key trends in U.S. cardiovascular health, and what clinicians should take away about hypertension, diabetes, obesity, and heart‑failure patterns. The discussion highlights implementation gaps, disparities, and how data can guide action in heart health.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.